New Diagnostics and Guidelines Developments Advancing Hepatitis C Elimination in the United States
New Diagnostics and Guidelines Developments Advancing Hepatitis C Elimination in the United States
Availability
On-Demand
Cost
$0.00
Credit Offered
0.25 AMA PRA Category 1 Credit
0.25 Participation Credit
  • Description
  • Learning Objectives
  • Accreditation Information
  • Faculty and Disclosures
  • Privacy Policy
  • Recommended
FOR MEMBERS ONLY! This session is an interview with Dr. Carolyn Wester, Director, Division of Viral Hepatitis for the Center for Disease Control and Prevention. She will discuss the latest in diagnosis and new guideline updates that will help in Hepatitis C elimination. This activity is for members only, but will be helpful to hepatologists, gastroenterologists, surgeons, transplant coordinators, nurses, nurse practitioners and physician assistants, pharmacists and patient advocates.


Start Date:  7/09/2025
Expiration Date: 7/09/2027

COPYRIGHT: All faculty in this activity have given their permission for publication ©2024 AASLD.
Upon completion of this activity, participants should be able to:
  • Identify what is needed to achieve HCV elimination
  • Use a progress toward HCV elimination has been made
The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Ponni Perumalswami, MD, FAASLD
Nothing to Disclose

Eduardo Yepez Guevara, MD
Nothing to Disclose

Carolyn Wester, MD, MPH
Nothing to Disclose

Philip Vutien, MD
Nothing to Disclose

Harrys Torres, MD, FAASLD
Research Grants: National Cancer Institute, Gilead, Merck
Powered By